All In Biotech

Drug Trial Radar · NCT06849713

Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL

A Multicenter Phase 2 Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax (BOSon) or Tacabrutideg (BGB-16673), Obinutuzumab, and Sonrotoclax (DOSon) in Treatment-Naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

May 16, 2025

Primary completion

Mar 1, 2028

Study completion Mar 1, 2030

Sponsor

Lead sponsor
Massachusetts General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
BeOne Medicines
First posted
Feb 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the proportion of participants who achieve undetectable measurable residual disease (uMRD) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Conditions

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma (SLL)

Interventions

  • ZanubrutinibDrug

    Bruton's Tyrosine Kinase (BTK) inhibitor

  • SonrotoclaxDrug

    B-cell lymphoma 2 (BCL2) protein inhibitor

  • ObinutuzumabDrug

    Anti-CD20 monoclonal antibody

  • TacabrutidegDrug

    Bruton's Tyrosine Kinase (BTK) degrader

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Undetectable MRD (uMRD) at Best ResponseTime frame: Day 1 to 2 years after final patient enrolled
  2. Proportion of Participants with Tumor Lysis Syndrome (TLS) Laboratory Abnormalities Requiring InterventionTime frame: Day 1 to completion date of sonrotoclax ramp-up

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.